DOSE Rapid Dose Therapeutics Corp.

CNQ · CA · Healthcare · Biotechnology · rapid-dose.com

0.1000CAD-16.67%Mkt Cap: 10.03M $P/E: —3d ago

Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system designed to rapidly release p…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap10.03M USD

Enterprise Value16.14M USD

Revenue (TTM)1.88M USD

Gross Profit992.70K USD

Net Income (TTM)-2.47M USD

Revenue/Share0.02 CAD

Last Price0.1000 CAD

Fiscal Year EndFeb 2026

MR QuarterMay 2026

Employees—

CountryCA

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA-12.16

EV/Revenue8.61

P/S6.42

P/B-2.18

EPS (TTM)-0.02

EPS (Forward)—

52W Range

0.080017% of range0.1950

52W High0.1950 CAD

52W Low0.0800 CAD

Profitability

Gross Margin49.15%

Oper. Margin-38.96%

EBITDA Margin-70.78%

Profit Margin-122.22%

ROE47.24%

ROA-103.26%

Growth

Revenue Growth-25.30%

Earnings Growth—

Cash Flow & Leverage

Operating CF-196.92K USD

CapEx (TTM)655 USD

FCF Margin-7.87%

FCF Yield-1.47%

Net Debt4.22M USD

Net Debt/EBITDA-3.18

Balance Sheet

Debt/Equity-0.72

Current Ratio0.04

Quick Ratio0.01

Book Value/Sh-0.06 CAD

Cash/Share0.00 CAD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 CAD

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Splits

Last Split1:5

Split DateFeb 16, 2018

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.137.78M

Float115.71M

Insiders17.02%

Institutions0.00%

Short Interest

Short Ratio0.1d

Short % Out.0.00%

Shares Short3.13K

Short (prev mo.)1.91K

Technical

SMA 500.1027 (-2.6%)

SMA 2000.1140 (-12.3%)

Beta-0.84

S&P 52W Chg13.94%

Avg Vol (30d)25.77K

Avg Vol (10d)33.28K

Technical Indicators

RSI (14)47.3

MACD0.0023

MACD Signal0.0013

MACD Hist.+0.0010

BB Upper0.1285 CAD

BB Middle0.1045 CAD

BB Lower0.0805 CAD

BB Width46.01%

ATR (14)0.0110 CAD

Vol Ratio (20d)0.73x